Aprovel
Catalog No: FT-0601598
CAS No: 138402-11-6
- Molecular Formula: 428.5
- Formula Weight: C25H28N6O
- Inchl Key: YOSHYTLCDANDAN-UHFFFAOYSA-N
- Inchl: InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
| Assay | Pack | Price | Stock | Action |
|---|---|---|---|---|
| 98% | 1g | N/A | N/A | |
| 98% | 5g | N/A | N/A | |
| 98% | Bulk Quantity | N/A | N/A |
| Melting_Point: | 180-181°C |
|---|---|
| CAS: | 138402-11-6 |
| MF: | C25H28N6O |
| Flash_Point: | 346.0±34.3 °C |
| Product_Name: | Irbesartan |
| Density: | 1.3±0.1 g/cm3 |
| FW: | 428.529 |
| Bolling_Point: | 648.6±65.0 °C at 760 mmHg |
| Refractive_Index: | 1.690 |
|---|---|
| Vapor_Pressure: | 0.0±1.9 mmHg at 25°C |
| Flash_Point: | 346.0±34.3 °C |
| LogP: | 4.51 |
| Bolling_Point: | 648.6±65.0 °C at 760 mmHg |
| FW: | 428.529 |
| PSA: | 87.13000 |
| Computational_Chemistry: | ['1. XlogP :41 ', '2. Hydrogen Bond Donor Count :1 ', '3. Hydrogen Bond Acceptor Count :5 ', '4. Rotatable Bond Count :7 ', '5. Isotope Atom Count :2 ', '6. TPSA 871 ', '7. Heavy Atom Count :32 ', '8. Topological Polar Surface Area :0 ', '9. Complexity :682 ', '10. Isotope Atom Count :0 ', '11. Defined Atom Stereocenter Count :0 ', '12. Undefined Atom Stereocenter Count :0 ', '13. Defined Bond Stereocenter Count :0 ', '14. Undefined Bond Stereocenter Count :0 ', '15. Covalently-Bonded Unit Count :1'] |
| Melting_Point: | 180-181°C |
| MF: | C25H28N6O |
| Exact_Mass: | 428.232452 |
| Molecular_Structure: | ['1 . Molar refractive index 12544 ', '2 . Molar volume 3282 ', '3 . Parachor （902K）8915 ', '4 . Surface tension 544 ', '5 . Polarizability 4973'] |
| Density: | 1.3±0.1 g/cm3 |
| More_Info: | ['1. Appearance 从96% Ethanol 结晶 ', '2. Melting point（ºC）180-181℃。'] |
| Hazard_Class: | 6.1 |
|---|---|
| Risk_Statements(EU): | R22 |
| RIDADR: | 3276 |
| Hazard_Codes: | Xn: Harmful; |
| HS_Code: | 2933990090 |
| Safety_Statements: | S26-S36/37/39 |
| Packing_Group: | III |
